首页>
外国专利>
Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
展开▼
机译:通过使用前列腺特异性抗原(PSA)和人腺激肽释放酶(hGK-1)来早期检测前列腺癌(CAP)
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention relates to a bioaffinity assay of prostate- specific antigen (PSA) comprising the measurement of either the concentration of total PSA (PSA-T), the concentration of free form of PSA (PSA-F) or the concentration of PSA complexed to alpha-1-antichymotrypsin (PSA-ACT), PSA- T being the sum of PSA-F and PSA-ACT. According to the invention, additionally the concentration of human glandular kallikrein (hGK-1) is measured. The concentrations of PSA-T and hGK-1 can be measured in one single assay or in separate assays. The sum of the concentrations of PSA- T and hGK-1 is used to determine the ratio a) PSA- F/(PSA-T+hGK-1) and/or b) PSA-ACT/(PSA-T+hGK-1). Both of these ratios are shown to have clinical utility for the discrimination of prostate cancer and benign prostatic hyperplasia.
展开▼